Product name: Pasireotide
Synonyms: Growth hormone release-inhibiting factor,
CAS NO.: 108736-35-2
Counter ion: Acetate
Format: Lyophilized powder
Description: The multireceptor-targeted SRL pasireotide (Signifor®) was initially approved in 2012 by the US Food and Drug Administration (FDA) for use in patients who were considered uncontrolled after surgical treatment of a corticotroph pituitary adenoma (Cushing’s disease). Somatotroph pituitary adenomas predominantly express somatostatin receptor (SSTR) types 2 and 5. The efficacy of pasireotide in reducing GH and IGF-1 levels and in shrinking tumor in patients with acromegaly has been evaluated in Phase III clinical trials.
Usage: For Scientific Research Use Only, Not for Human Use.